Form 8-K ALNYLAM PHARMACEUTICALS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Alnylam secures $500 million revolving credit facility
October 3, 2025 4:19 PM EDTAlnylam Pharmaceuticals Inc. (NASDAQ: ALNY) entered into a $500 million revolving credit agreement on September 30, 2025, with Bank of America N.A. serving as administrative agent.
The revolving credit facility includes a $150 million letter of credit sublimit and allows the company to use proceeds for working capital and general... More
